Nanobiotix Share: Biotech Declines 4.5%, One of the Heaviest Drops on the SBF 120
The Paris-based biotech company specializing in nanomedicine for oncology extends its downward slide at midday, in an SBF 120 index itself oriented downward. The stock is approaching the end of a particularly heavy monthly sequence that has wiped out its main technical benchmarks.
A Decline of 4.57% That Extends the Monthly Fall of the Stock
Nanobiotix share drops 4.57% to €21.32 versus €22.34 at the previous close, placing it among the heaviest declines on the SBF 120, with the index itself retreating 0.77% at midday. The movement is part of a longer downturn: the stock loses 22.75% over one week and 35.71% over one month, while maintaining a gain of 17% over one year. The price thus falls below the €22.34 threshold that served as support and distances itself from the MA20 (€28.08), which now towers above it by 24%.
The MA200, at €28.74, is also clearly well above the price. The RSI at 24 reflects an oversold configuration following this continuous decline sequence, without prejudging what comes next. Over the past five trading days, the stock has already been the worst performer on the index on October 2 and October 7, with only one notable rebound on October 5.
Cash Position of €110.9 Million Announced at End of September to Finance Operations Until 2029
On the fundamental side, the operational and financial update for the first half of 2026, published on September 24, reports cash of €110.9 million, compared to €52.8 million at the end of December 2025, following a capital increase of approximately €86 million completed in May. The company estimates that these liquid assets cover its operations through 2029 and sees no substantial doubt regarding the continuation of its business over the next twelve months. Nanobiotix is developing its radioenhancer NBTXR3 (JNJ-1900) associated with radiotherapy, in partnership with Johnson & Johnson.
The stock also trades on the Nasdaq in the form of ADRs (NBTX), at a ratio of one ADR per ordinary share, and remains eligible for PEA investment plans on its Paris listing. The next key technical level remains the €22.34 threshold now ceded, which the stock will need to reclaim to recover the ground lost since early September.
